ETODOLAC DOSAGE FORMULATION AND PROCESS FOR PREPARING THE SAME
DOI:
https://doi.org/10.61841/tqg8m204Keywords:
Analgesic, Anti-inflammatory, Etodolac, NSAID, Osteoarthritis, Rheumatoid arthritisAbstract
Etodolac belongs to the class of “non-steroidal anti-inflammatory class of drugs” (NSAIDs) with anti-inflammatory, analgesic and anti-pyretic effects. At lower doses, NSAIDs provide analgesic properties, while higher doses are needed to produce anti-inflammatory action. The treatment of osteoarthritis, rheumatoid arthritis and relatively extreme post-surgical pain relief is effective with Etodolac. Etodolac was used in the treatment of ankylosing spondylitis, post-operative pain (dental, orthopedic or obstetric surgery) and in non surgical pain (tendonitis, lower back pain, gout or sports injury). The goal of the research is to include a bilayer tablet formulation of etodoloac for rapid uptake and eventual rapid onset of action to relieve acute pain. Using various excipients, the extended discharge comprises is prepared by wet granulation. The formulation comprises of effective amount of active ingredient etodolac or salts thereof in combination with compressible powder, superdisintegrant and effervescent agent.
Downloads
References
[1] J. S. Smolen, D. Aletaha, and I. B. McInnes, “Rheumatoid arthritis,” The Lancet. 2016.
[2] A. W. Yousuf, A. M. Yousuf, and A. U. Erum, “Occupation and sports participation as risk factors for the development and progression of knee osteoarthritis,” Int. J. Res. Med. Sci. Yousuf AW al. Int J Res Med Sci, vol. 5, no. 6, pp. 2278–2281, 2017.
[3] N. H.-A. of internal medicine and undefined 1992, “Knee pain is the malady—not osteoarthritis,” annals.org.
[4] F. Silverstein, G. Faich, J. Goldstein, L. S.- Jama, and undefined 2000, “Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized,” jamanetwork.com.
[5] J. E. Frampton, “Tapentadol immediate release: A review of its use in the treatment of moderate to severe acute pain,” Drugs, vol. 70, no. 13. pp. 1719–1743, 2010.
[6] K. R. Georgy, R. M. Farid, R. Latif, and E. R. Bendas, “A new design for a chronological release profile of etodolac from coated bilayer tablets: In-vitro and in-vivo assessment,” J. Adv. Res., 2019.
[7] S. B. Gondkar, N. R. Patil, and R. B. Saudagar, “Formulation development and characterization of etodolac loaded transethosomes for transdermal delivery,” Res. J. Pharm. Technol., 2017.
[8] - Google Scholar.” [Online]. Available: fects+in+musculoskeletal+and+postoperative+pain.+J+Clin+Diagn+Res+2014%3B+8%3A+LC11
LC15.&btnG=. [Accessed: 23-Nov-2019].
[9] A. Pareek, N. Chandurkar, … R. A.-T. C. journal, and undefined 2010, “Efficacy and safety of etodolac paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation,” journals.lww.com.
[10] B. G. Donley, T. Moore, J. Sierra, J. Gozdanovic, and R. Smith, “The efficacy of oral nonsteroidal antiinflammatory medication (NSAID) in the treatment of plantar fasciitis: A randomized, prospective, placebocontrolled study,” Foot Ankle Int., 2007.
[11] N. Kaur, H. Singh, and A. C. Gupta, “Randomized controlled trial of etodolac versus combination of etodolac and eperisone in patients of knee osteoarthritis,” Pain Res. Treat., 2013.
[12] T. J. Schnitzer and G. Constantine, “Etodolac (Lodine®) in the treatment of osteoarthritis: Recent studies,” J.
Rheumatol., 1997.
[13] “(No Title),” 2013.
[14] - Google Scholar.” [Online]. Available: Bagal+VA%2C+Singh+K.+Simultaneous+estimation+of+etodolac+and+paracetamol+in+bulk+drug+dosag
e+form+by+RP-HPLC.+IJAPA+2013%3B+3%3A+56-67.&btnG=. [Accessed: 23-Nov-2019].
[15] A. Hayashi, K. Yoshida, and H. Nakayama, “Complex formation of etodolac with hydrotalcite in methanol,” Bull. Chem. Soc. Jpn., 2013.
[16] S. K. Tirunagari, S. Derry, R. A. Moore, H. J. McQuay, and M. Moore, “Single dose oral etodolac for acute postoperative pain in adults,” Cochrane Database of Systematic Reviews. 2009.
[17] S. Ito et al., “Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia,” J. Pharmacol. Exp. Ther., 2012.
[18] B. P. Monteiro-Steagall, P. V. M. Steagall, and B. D. X. Lascelles, “Systematic review of nonsteroidal antiinflammatory drug-induced adverse effects in dogs,” J. Vet. Intern. Med., 2013.
[19] S. Salah, A. A. Mahmoud, and A. O. Kamel, “Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: Ex vivo permeation and in vivo pharmacokinetic studies,” Drug Deliv., 2017.
[20] M. U. Din, S. M. Din, and T. P. Shukla, “An Overview on Bilayered Tablet Technology,” J. Sci. Res., vol. 9, no. 1, pp. 6–15, 2014.
[21] N. Pujara, R. Gokani, J. P.-I. journal of, and undefined 2012, “Bilayer tablet–an emerging trend,” researchgate.net.
[22] A. Kumar, K. V. Gernaey, T. De Beer, and I. Nopens, “Model-based analysis of high shear wet granulation from batch to continuous processes in pharmaceutical production - A critical review,” European Journal of Pharmaceutics and Biopharmaceutics. 2013.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
